We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Two Next Generation Diagnostic Platforms Available in Europe

By LabMedica International staff writers
Posted on 19 Feb 2009
Two next-generation clinical laboratory systems are now commercially available in Europe.

The Vitros 5600 integrated system and the high-capacity Vitros 3600 immunodiagnostic system are next generation platforms that were designed to address the needs of modern clinical labs, giving patients and clinicians high-quality and reliable test results.

The Vitros 5600 system is designed to integrate clinical chemistry and immunoassay testing and can perform more than 100 different chemistry, immunoassay, and infectious disease assays on a single, high-quality system. More...
Individual samples are accessed independently and in parallel for chemistry and immunoassay testing. This approach optimizes turnaround time and productivity by intelligently accounting for variable sample and test mixes. In addition to its current broad menu, which includes user-defined applications, the Vitros 5600 integrated system will be able to run new tests for earlier detection of diseases.

The Vitros 3600 immunodiagnostic system is designed for medium- to high-volume labs. Three Vitros technologies are combined into a single system: Microwell technology that with enhanced chemiluminescence enables exceptional assay performance with small sample volume requirements across a broad range of diseases; MicroSensor technology that automatically performs sample quality indices checks on the immunoassay system; and Intellicheck technology that verifies analytical performance and reduces error potential by providing real-time operator notification and tracking.

The systems were developed by Ortho Clinical Diagnostics (High Wycombe, UK). David Atkins, Ph.D., vice president of Ortho Clinical Diagnostics, said, "Our mission has always been to give health professionals the highest quality tools to determine the best treatment. The introduction of the Vitros 5600 integrated system and Vitros 3600 immunodiagnostic system continues this mission with next generation instruments that have a broad, world class menu of assays and the capacity to support future high-impact tests."

Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, delivers high quality in-vitro diagnostic products that give health care professionals around the world the knowledge they need to make better treatment decisions sooner.

Related Links:

Ortho Clinical Diagnostics




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.